GR-159897: Difference between revisions

Latest revision as of 06:36, 16 February 2025

GR-159897[edit]

GR-159897 is a chemical compound that acts as a selective antagonist for the neurokinin 1 receptor (NK1 receptor). It is primarily used in scientific research to study the role of NK1 receptors in various physiological and pathological processes.

Mechanism of Action[edit]

GR-159897 functions by binding to the NK1 receptor, thereby inhibiting the action of its natural ligand, substance P. Substance P is a neuropeptide involved in the transmission of pain and other sensory signals. By blocking the NK1 receptor, GR-159897 can modulate the effects of substance P, making it a valuable tool in the study of pain mechanisms and other conditions where substance P is implicated.

Applications in Research[edit]

GR-159897 is used extensively in preclinical research to explore the potential therapeutic benefits of NK1 receptor antagonism. Some of the key areas of research include:

Pain Management: By blocking the action of substance P, GR-159897 is used to investigate new pain relief strategies, particularly in chronic pain conditions.
Psychiatric Disorders: NK1 receptor antagonists like GR-159897 are studied for their potential in treating depression and anxiety disorders.
Inflammatory Diseases: The role of substance P in inflammation makes GR-159897 a useful compound in studying inflammatory pathways and potential treatments.

Chemical Properties[edit]

GR-159897 is characterized by its specific chemical structure, which allows it to selectively bind to the NK1 receptor. The compound's structure is depicted in the image to the right, highlighting its molecular configuration.

Safety and Handling[edit]

As with many research chemicals, GR-159897 should be handled with care in a laboratory setting. Appropriate safety measures, including the use of personal protective equipment (PPE) and adherence to safety protocols, are essential to ensure safe handling and experimentation.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-'''GR-159897''' is a drug that acts as a selective, non-peptide [[antagonist]] at the [[neurokinin 1 receptor]]. It was developed by [[GlaxoSmithKline]] and has been researched for various applications such as the treatment of [[anxiety]], [[depression]], [[nausea]], and [[emesis]] (vomiting), but was not successful in clinical trials and has not been adopted for medical use.
+== GR-159897 ==
-==Pharmacology==
+[[File:GR-159,897_chemical_structure.png|thumb|right|Chemical structure of GR-159897]]
-GR-159897 is a potent and selective antagonist for the neurokinin 1 (NK1) receptor. The NK1 receptor is a G protein-coupled receptor located in the central and peripheral nervous system, which is activated by the neuropeptide substance P. Antagonism of this receptor by GR-159897 can potentially modulate the effects of substance P, which is involved in pain perception, stress, and emesis.
-==Clinical Trials==
+'''GR-159897''' is a chemical compound that acts as a selective antagonist for the [[neurokinin 1 receptor]] (NK1 receptor). It is primarily used in scientific research to study the role of NK1 receptors in various physiological and pathological processes.
-GR-159897 has been investigated in clinical trials for its potential therapeutic effects in various conditions. However, it did not show significant efficacy in these trials and has not been approved for medical use.
-===Anxiety and Depression===
+== Mechanism of Action ==
-In preclinical studies, GR-159897 showed potential as a treatment for anxiety and depression. However, in clinical trials, it did not demonstrate significant efficacy compared to placebo.
-===Nausea and Emesis===
+GR-159897 functions by binding to the NK1 receptor, thereby inhibiting the action of its natural ligand, [[substance P]]. Substance P is a neuropeptide involved in the transmission of pain and other sensory signals. By blocking the NK1 receptor, GR-159897 can modulate the effects of substance P, making it a valuable tool in the study of pain mechanisms and other conditions where substance P is implicated.
-GR-159897 has also been studied for its potential to treat nausea and emesis, due to the role of the NK1 receptor in these conditions. However, it did not show significant efficacy in clinical trials.
-==Development==
+== Applications in Research ==
-GR-159897 was developed by the pharmaceutical company GlaxoSmithKline. Despite its lack of success in clinical trials, research into NK1 receptor antagonists continues, due to the potential therapeutic applications of modulating this receptor.
+GR-159897 is used extensively in [[preclinical research]] to explore the potential therapeutic benefits of NK1 receptor antagonism. Some of the key areas of research include:
+* '''Pain Management''': By blocking the action of substance P, GR-159897 is used to investigate new pain relief strategies, particularly in chronic pain conditions.
+* '''Psychiatric Disorders''': NK1 receptor antagonists like GR-159897 are studied for their potential in treating [[depression]] and [[anxiety disorders]].
+* '''Inflammatory Diseases''': The role of substance P in inflammation makes GR-159897 a useful compound in studying inflammatory pathways and potential treatments.
+== Chemical Properties ==
+GR-159897 is characterized by its specific chemical structure, which allows it to selectively bind to the NK1 receptor. The compound's structure is depicted in the image to the right, highlighting its molecular configuration.
+== Safety and Handling ==
+As with many research chemicals, GR-159897 should be handled with care in a laboratory setting. Appropriate safety measures, including the use of personal protective equipment (PPE) and adherence to safety protocols, are essential to ensure safe handling and experimentation.
+== Related Pages ==
-==See Also==
 * [[Neurokinin 1 receptor]]
 * [[Substance P]]
-* [[GlaxoSmithKline]]
+* [[Pain management]]
+* [[Depression]]
+* [[Anxiety disorders]]
-[[Category:Drugs]]
 [[Category:Pharmacology]]
-[[Category:Clinical trials]]
+[[Category:Research chemicals]]
-[[Category:GlaxoSmithKline]]
-{{stub}}